RAT16

Question 1

Pyridostigmine

Answer 1

Quaternary reversible anticholinesterase, strengthen muscle contraction; MG

Question 2

Azathioprine

Answer 2

Converted to 6-mercaptopurine in liver, then inhibits purine synthesis, blocks Rac1 activation; MG

Question 3

Neostigmine

Answer 3

Reversible anticholinesterase; terminates non-depolarizing neuromuscular blocking agents

Question 4

Donepezil (oral), Rivastigmine (patch)

Answer 4

Tertiary anticholinesterase, prevent ACh hydrolysis in CNS; AD

Question 5

Memantine

Answer 5

Low-moderate affinity block of NMDA channel, intended to reduce excitotoxic neuronal dysfunction in CNS; AD

Question 6

Selegiline, Rasagiline

Answer 6

MAO-B inhibitors, antioxidants, increase DA in basal ganglia

Question 7

Ropinirole, Pramipexole, Rotigotine

Answer 7

Long-acting D2 receptor agonists, reduce activity in indirect pathway

Question 8

L-DOPA

Answer 8

precursor for dopamine

Question 9

Carbidopa

Answer 9

Peripheral DOPA decarboxylase inhibitor, increase availiability of L-DOPA and stop peripheral synthesis of dopamine

Question 10

Entacapone

Answer 10

Peipheral COMT inhibitor, increase L-DOPA transport to CNS

Question 11

Sinemet/Stalevo

Answer 11

L-DOPA + Carbidopa, L-DOPA + Carbidopa + Entacapone

Question 12

Amantadine

Answer 12

Low-moderate affinity block of NMDA channel, stops dyskinesias later on in disease